It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic heart failure (CHF) is the final outcome of many cardiovascular diseases, and is a severe health issue faced by the elderly population. Mixed lineage kinase 3 (MLK3), a member of MAP3K family, is associated with aging, inflammation, oxidative stress, and related diseases, such as CHF. MLK3 has also been reported to play an important role in protecting against cardiomyocyte injury; however, its function in myocardial fibrosis is unknown. To investigate the role of MLK3 in myocardial fibrosis, we inhibited the expression of MLK3, and examined cardiac function and remodeling in TAC mice. In addition, we assessed the expression of MLK3 protein in ventricular cells and its downstream associated protein. We found that MLK3 mainly regulates NF-κB/NLRP3 signaling pathway-mediated inflammation and that pyroptosis causes myocardial fibrosis in the early stages of CHF. Similarly, MLK3 mainly regulates the JNK/p53 signaling pathway-mediated oxidative stress and that ferroptosis causes myocardial fibrosis in the advanced stages of CHF. We also found that promoting the expression of miR-351 can inhibit the expression of MLK3, and significantly improve cardiac function in mice subjected to TAC. These results suggest the pyroptosis and ferroptosis induced by MLK3 signaling in cardiomyocytes are essential for adverse myocardial fibrosis, in response to pressure overload. Furthermore, miR-351, which has a protective effect on ventricular remodeling in heart failure caused by pressure overload, may be a key target for the regulation of MLK3.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Guangzhou University of Chinese Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, The First Clinical Medical School, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, Lingnan Medical Research Center, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685)
2 Guangzhou University of Chinese Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, The First Clinical Medical School, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, Lingnan Medical Research Center, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou Key Laboratory of Chinese Medicine for Prevention and Treatment of Chronic Heart Failure, Guangzhou, China (GRID:grid.411866.c)
3 Guangzhou University of Chinese Medicine, The First Clinical Medical School, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, Lingnan Medical Research Center, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685)
4 Guangzhou University of Chinese Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, The First Clinical Medical School, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou University of Chinese Medicine, Lingnan Medical Research Center, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685); Guangzhou Key Laboratory of Chinese Medicine for Prevention and Treatment of Chronic Heart Failure, Guangzhou, China (GRID:grid.411866.c); National Clinical Research Base of Traditional Chinese Medicine, Guangzhou, China (GRID:grid.411866.c)